IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 8193 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 ╗   Next article
 ╗   Previous article
 ╗   Table of Contents

Resource Links
 ╗   Similar in PUBMED
 ╗  Search Pubmed for
 ╗  Search in Google Scholar for
 ╗Related articles
 ╗   Citation Manager
 ╗   Access Statistics
 ╗   Reader Comments
 ╗   Email Alert *
 ╗   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded143    
    Comments [Add]    

Recommend this journal


Year : 1997  |  Volume : 29  |  Issue : 6  |  Page : 420-425

Clinical evaluation of prazosin in symptomatic benign prostatic hyperplasia ľan Indian experience

Correspondence Address:
S Basalingappa

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Objective: To investigate the effectiveness of prazosin, a selective alpha-l adrenoceptor antagonist in the treatment of benign prostatic hyperplasia (BPH) in Indian population. Methods: Twenty six patients who had obstructive and irritative symptoms in addition to enlarged prostate assessed by Boyarsky symptom score, rectal examination, ultrasonography, uroflowmetry were included. Patients with urinary tract infections, diabetes mellitus, cerebrovascular, cardiovascular diseases and those taking medications known to influence vesicourethral functions were excluded. The patients were administered prazosin (prazopress) 0.5 mg in the morning and 0.5 mg at night in the first week and subsequently, 0.5 mg morning and 1 mg at night for another 3 weeks. Pretreatment and post-treatment assessment criteria were compared statistically using Student's 't' test. Results: Voiding symptoms, assessed on the basis of Boyarsky scale and micturition history; urinary flow rates measured by uroflowmeter were significantly improved (pc 0.001). Clinical safety was assessed by measurement of blood pressure, volunteered complaints and by questionnaire. At this dosage schedule the clinical safety was good. Conclusion: Prazosin is effective in the dose of 0.5 mg (morning) and 1 mg (night) in the treatment of patients with symptomatic BPH. The incidence of adverse events related to its vasodilator properties were minimal.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow